The Proof-of-Concept Grants program will favour those applications that focus on challenging new directions in research into Alzheimer’s disease and other dementias. The Proof-of-Concept Grant will support investigators with innovative, potentially high-risk, high-yield exploration into dementia research. The maximum amount awarded is $100,000; the grant can be held for a maximum of three (3) years.

The specific objectives of this funding opportunity are to advance knowledge and strategies on how to increase vaccine confidence in populations experiencing conditions of marginalization, Indigenous Peoples and/or populations who have historically been under-vaccinated, including how to address structural, contextual, intersectional and historical barriers to vaccination by:

1. Addressing knowledge gaps related to understanding the causes and contributing factors to lower vaccination confidence associated with COVID-19, and provide communities, healthcare providers, and public health and health system leaders with actionable evidence to improve vaccine confidence and uptake in clinical and/or community contexts; and
2. Designing, implementing and/or evaluating promising interventions to increase vaccine confidence, including a focus on which approaches are most effective, in which populations and contexts, and why (implementation science approach).

First Nations, Inuit and Métis including Urban Indigenous communities

For applications addressing vaccine confidence among Indigenous Peoples applicants are encouraged to use a distinctions-based approach and to identify structural, contextual, and historical barriers that explain inequities in uptake and inform strategies for meaningful and culturally safe solutions. Projects must prioritize First Nations, Inuit and Métis Peoples and communities, including Urban Indigenous communities, in leading their own research, and include an approach based on Indigenous knowledge systems.

Applicants whose proposed research will involve Indigenous Peoples should consult the Tri-Council Policy Statement (TCPS 2 - Chapter 9 Research Involving the First Nations, Inuit and Métis Peoples of Canada) for guidance on research design.

The FY21 Defense Appropriations Act provides funding to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support research addressing Duchenne pathobiology and discovery and development of therapeutics, related devices and tools. The managing agent for the anticipated program announcements/funding opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY21 DMDRP program announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.    

https://cdmrp.army.mil/funding/dmdrp

Idea Development Award – Preproposal due August 11, 2021

Translational Research Award - New for FY21 – Preproposal due August 11, 2021

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final program announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

This funding supports projects that focus on the following objective:

• develop and carry out services and supports to help increase the social inclusion and wellbeing of vulnerable children and youth

Projects should target children and youth who are at highest risk of, or are experiencing negative impacts to their physical and mental wellbeing due to social isolation.

Find more information about the Social Development Partnerships Program

As organizations can only submit one application to this or the Financial Empowerment of Low-Income People call, interested applicants are asked to contact the Office of Research to indicate their intention to apply no later than June 7.

This funding supports projects that focus on the following objective:

• develop and carry out financial empowerment services and supports to help increase the financial wellbeing of low-income adults

Projects must address more than 1 aspect of financial wellbeing, and must offer more than 1 type of service.

Find more information about the Social Development Partnerships Program.

As organizations can only submit one application to this or the Social Inclusion of Vulnerable Children and Youth call, interested applicants are asked to contact the Office of Research to indicate their intention to apply no later than June 7.

The specific objectives of this funding opportunity are:

• Promote the career development of mid-career investigators from Canadian academic institutions in vaccine research for infectious diseases;
• Create new knowledge in vaccine research for emerging threats through a mutually beneficial exchange of expertise between Canadian mid-career investigators and CEPI, and support the mobilization of the knowledge created to relevant knowledge users and other stakeholders; and
• Position mid-career Canadian investigators as international leaders in vaccine research for infectious diseases.

The Forest Sector Investment and Innovation Program provides funding for strategic investments in the forest sector that:

• improve productivity and innovation
• enhance competitiveness
• support new market access
• provide benefits to Ontario’s broader forest sector
• strengthen regional economies

Support is available under two project categories:

• business projects
• collaboration projects

Canada-U.S. Fulbright Visiting Research Chairs are normally awarded for one semester, though successful applicants may opt to extend their stay to a full year. Dates of the awards should coincide with the academic year of the host institution.

Provisions for Fulbright Visiting Chair awards are particular to each institution, though normally carry a value of US$25,000 for one semester. Basic health insurance is also provided, along with visa services and on campus support. Enrichment opportunities are available through the Fulbright Mobility Initiative in Canada and the Outreach Lecturing Fund in the United States. Faculty sabbatical, leave-of-absence, or retirement pay may be used concurrently with Fulbright support.

All awards are subject to available funding, approval by the J. William Fulbright Foreign Scholarship Board (FSB), and compliance with FSB guidelines.

Canadian applicants interested in applying for Traditional and Research Chair Fulbright Scholar awards are asked to complete an online application.

The FY21 Defense Appropriations Act provides funding to the Department of Defense Rare Cancers Research Program (RCRP) to support research of exceptional scientific merit in the area of rare cancers research.  The managing agent for the anticipated program announcements/funding opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY21 RCRP program announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.    

Vision Statement

To greatly improve outcomes for people with rare cancer through discovery and community building, and expansion of knowledge across the cancer landscape

Mission Statement

Elevate rare cancers research to enable clinically impactful discoveries for the benefit of Service Members, their families, Veterans, and the American public

Concept Award and Idea Development Award applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

• Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.

• Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.

• Therapy: Identify novel therapeutic strategies, including drug repurposing.

Resource and Community Development Award applications submitted to the FY21 RCRP must address the Focus Areas below:

• Platform Development: Development of platforms (such as tumor tissue repository with clinical annotation, centralized databanks, patient registry with common data structure, research model and Omics database, longitudinal studies of natural history, and treatment response) for multiple rare cancers, to allow sharing of data, bio-specimens, and resources.

https://cdmrp.army.mil/funding/rcrp

Concept Award – Letter of Intent due July 11, 2021

Investigators at or above the level of postdoctoral fellow.

• Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers.  Proof-of-concept is the anticipated outcome.
• Reviewers will be blinded to the identity of the Principal Investigator, collaborators, and their organization(s).
• Submission must address at least one of the FY21 Focus Areas of Biology and Etiology, Research Model, and/or Therapy.
• Preliminary data are not required.
• Clinical trials are not allowed.
• Maximum funding of $100,000 for direct costs (plus indirect costs) 
• Maximum period of performance is 1 year

Idea Development Award – Preapplication is due July 13, 2021

Investigators at or above the level of Assistant Professor.

• Preproposal submission is required; application submission is by invitation only.
• Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field.
• Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required. 
• Submission must address at least one of the FY21 Focus Areas of Biology and Etiology, Research Model, and/or Therapy.
• Clinical trials are not allowed.
  • Maximum funding of $350,000 for direct costs (plus indirect costs)  
  • Maximum period of performance is 3 years

Resource and Community Development Award – Preapplication due July 13, 2021

Investigators at or above the level of Assistant Professor.

• Preproposal submission is required; application submission is by invitation only.
• Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community. 
• Supports platform development or infrastructure that can be applied to multiple rare cancers.
• Preliminary data are not required but may be included (translational research and clinical studies may be included).
• Submission must address the Platform Development Focus Area.
• Clinical trials are not allowed.
  • Maximum funding of $600,000 for direct costs (plus indirect costs) 
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final program announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org